vs
亚什兰（ASH）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
亚什兰的季度营收约是REPLIGEN CORP的2.0倍（$386.0M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs -3.1%，领先9.8%），REPLIGEN CORP同比增速更快（13.6% vs -4.7%），亚什兰自由现金流更多（$111.0M vs $17.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs -18.1%）
亚什兰是一家总部位于美国特拉华州威尔明顿的化工企业，1924年始创于肯塔基州亚什兰市，最初以炼油业务起家，1994年迁至现总部。公司拥有多个业务板块，覆盖化工中间体与溶剂、复合材料、工业特种化学品、个人及家居护理、制药、食品饮料以及农业相关领域，2017年之前曾是胜牌润滑油的主要生产商。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
ASH vs RGEN — 直观对比
营收规模更大
ASH
是对方的2.0倍
$197.9M
营收增速更快
RGEN
高出18.3%
-4.7%
净利率更高
RGEN
高出9.8%
-3.1%
自由现金流更多
ASH
多$93.4M
$17.6M
两年增速更快
RGEN
近两年复合增速
-18.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $386.0M | $197.9M |
| 净利润 | $-12.0M | $13.3M |
| 毛利率 | 27.2% | 52.5% |
| 营业利润率 | -1.6% | 9.0% |
| 净利率 | -3.1% | 6.7% |
| 营收同比 | -4.7% | 13.6% |
| 净利润同比 | 92.7% | 143.9% |
| 每股收益（稀释后） | $-0.26 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASHRGEN
| Q4 25 | $386.0M | $197.9M | ||
| Q3 25 | $477.0M | $188.8M | ||
| Q2 25 | $463.0M | $182.4M | ||
| Q1 25 | $479.0M | $169.2M | ||
| Q4 24 | $405.0M | $174.1M | ||
| Q3 24 | $521.0M | $154.9M | ||
| Q2 24 | $544.0M | $154.1M | ||
| Q1 24 | $575.0M | $151.3M |
净利润ASHRGEN
| Q4 25 | $-12.0M | $13.3M | ||
| Q3 25 | $31.0M | $14.9M | ||
| Q2 25 | $-742.0M | $14.9M | ||
| Q1 25 | $31.0M | $5.8M | ||
| Q4 24 | $-165.0M | $-30.3M | ||
| Q3 24 | $17.0M | $-654.0K | ||
| Q2 24 | $6.0M | $3.3M | ||
| Q1 24 | $120.0M | $2.1M |
毛利率ASHRGEN
| Q4 25 | 27.2% | 52.5% | ||
| Q3 25 | 33.3% | 53.2% | ||
| Q2 25 | 28.5% | 50.0% | ||
| Q1 25 | 30.7% | 53.6% | ||
| Q4 24 | 27.4% | 26.1% | ||
| Q3 24 | 33.2% | 50.0% | ||
| Q2 24 | 34.2% | 49.8% | ||
| Q1 24 | 28.0% | 49.5% |
营业利润率ASHRGEN
| Q4 25 | -1.6% | 9.0% | ||
| Q3 25 | 12.8% | 8.9% | ||
| Q2 25 | -152.9% | 7.6% | ||
| Q1 25 | 10.6% | 3.9% | ||
| Q4 24 | -44.2% | -17.7% | ||
| Q3 24 | 6.1% | -5.1% | ||
| Q2 24 | -11.2% | 1.0% | ||
| Q1 24 | 3.7% | 1.3% |
净利率ASHRGEN
| Q4 25 | -3.1% | 6.7% | ||
| Q3 25 | 6.5% | 7.9% | ||
| Q2 25 | -160.3% | 8.2% | ||
| Q1 25 | 6.5% | 3.4% | ||
| Q4 24 | -40.7% | -17.4% | ||
| Q3 24 | 3.3% | -0.4% | ||
| Q2 24 | 1.1% | 2.2% | ||
| Q1 24 | 20.9% | 1.4% |
每股收益（稀释后）ASHRGEN
| Q4 25 | $-0.26 | $0.24 | ||
| Q3 25 | $0.83 | $0.26 | ||
| Q2 25 | $-16.21 | $0.26 | ||
| Q1 25 | $0.65 | $0.10 | ||
| Q4 24 | $-3.50 | $-0.55 | ||
| Q3 24 | $0.34 | $-0.01 | ||
| Q2 24 | $0.12 | $0.06 | ||
| Q1 24 | $2.39 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $304.0M | $767.6M |
| 总债务越低越好 | $1.4B | $542.2M |
| 股东权益账面价值 | $1.9B | $2.1B |
| 总资产 | $4.5B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.74× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资ASHRGEN
| Q4 25 | $304.0M | $767.6M | ||
| Q3 25 | $215.0M | $748.7M | ||
| Q2 25 | $207.0M | $708.9M | ||
| Q1 25 | $168.0M | $697.2M | ||
| Q4 24 | $219.0M | $757.4M | ||
| Q3 24 | $300.0M | $784.0M | ||
| Q2 24 | $399.0M | $809.1M | ||
| Q1 24 | $439.0M | $780.6M |
总债务ASHRGEN
| Q4 25 | $1.4B | $542.2M | ||
| Q3 25 | $1.4B | $537.9M | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | $525.6M | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.3B | — |
股东权益ASHRGEN
| Q4 25 | $1.9B | $2.1B | ||
| Q3 25 | $1.9B | $2.1B | ||
| Q2 25 | $1.9B | $2.1B | ||
| Q1 25 | $2.6B | $2.0B | ||
| Q4 24 | $2.6B | $2.0B | ||
| Q3 24 | $2.9B | $2.0B | ||
| Q2 24 | $3.0B | $2.0B | ||
| Q1 24 | $3.1B | $2.0B |
总资产ASHRGEN
| Q4 25 | $4.5B | $2.9B | ||
| Q3 25 | $4.6B | $2.9B | ||
| Q2 25 | $4.6B | $2.9B | ||
| Q1 25 | $5.2B | $2.9B | ||
| Q4 24 | $5.2B | $2.8B | ||
| Q3 24 | $5.6B | $2.8B | ||
| Q2 24 | $5.7B | $2.9B | ||
| Q1 24 | $5.9B | $2.8B |
负债/权益比ASHRGEN
| Q4 25 | 0.74× | 0.26× | ||
| Q3 25 | 0.73× | 0.26× | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.52× | — | ||
| Q4 24 | 0.51× | 0.27× | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.45× | — | ||
| Q1 24 | 0.42× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $125.0M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $111.0M | $17.6M |
| 自由现金流率自由现金流/营收 | 28.8% | 8.9% |
| 资本支出强度资本支出/营收 | 3.6% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | $200.0M | $93.9M |
8季度趋势，按日历期对齐
经营现金流ASHRGEN
| Q4 25 | $125.0M | $25.7M | ||
| Q3 25 | $40.0M | $48.1M | ||
| Q2 25 | $115.0M | $28.6M | ||
| Q1 25 | $9.0M | $15.0M | ||
| Q4 24 | $-30.0M | $39.2M | ||
| Q3 24 | $80.0M | $49.3M | ||
| Q2 24 | $127.0M | $42.2M | ||
| Q1 24 | $54.0M | $44.7M |
自由现金流ASHRGEN
| Q4 25 | $111.0M | $17.6M | ||
| Q3 25 | $6.0M | $43.4M | ||
| Q2 25 | $95.0M | $21.5M | ||
| Q1 25 | $-12.0M | $11.4M | ||
| Q4 24 | $-53.0M | $33.6M | ||
| Q3 24 | $42.0M | $42.3M | ||
| Q2 24 | $98.0M | $37.4M | ||
| Q1 24 | $20.0M | $36.4M |
自由现金流率ASHRGEN
| Q4 25 | 28.8% | 8.9% | ||
| Q3 25 | 1.3% | 23.0% | ||
| Q2 25 | 20.5% | 11.8% | ||
| Q1 25 | -2.5% | 6.8% | ||
| Q4 24 | -13.1% | 19.3% | ||
| Q3 24 | 8.1% | 27.3% | ||
| Q2 24 | 18.0% | 24.3% | ||
| Q1 24 | 3.5% | 24.0% |
资本支出强度ASHRGEN
| Q4 25 | 3.6% | 4.1% | ||
| Q3 25 | 7.1% | 2.5% | ||
| Q2 25 | 4.3% | 3.9% | ||
| Q1 25 | 4.4% | 2.1% | ||
| Q4 24 | 5.7% | 3.2% | ||
| Q3 24 | 7.3% | 4.5% | ||
| Q2 24 | 5.3% | 3.1% | ||
| Q1 24 | 5.9% | 5.5% |
现金转化率ASHRGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | 1.29× | 3.23× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | 0.29× | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.71× | — | ||
| Q2 24 | 21.17× | 12.70× | ||
| Q1 24 | 0.45× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
RGEN
暂无分部数据
